Logo image of VVOS

VIVOS THERAPEUTICS INC (VVOS) Stock Fundamental Analysis

NASDAQ:VVOS - Nasdaq - US92859E2072 - Common Stock - Currency: USD

2.28  +0.19 (+9.09%)

After market: 2.27 -0.01 (-0.44%)

Fundamental Rating

3

Overall VVOS gets a fundamental rating of 3 out of 10. We evaluated VVOS against 102 industry peers in the Health Care Providers & Services industry. VVOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, VVOS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VVOS had negative earnings in the past year.
VVOS had a negative operating cash flow in the past year.
VVOS had negative earnings in each of the past 5 years.
In the past 5 years VVOS always reported negative operating cash flow.
VVOS Yearly Net Income VS EBIT VS OCF VS FCFVVOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -72.86%, VVOS is doing worse than 95.10% of the companies in the same industry.
VVOS's Return On Equity of -140.01% is on the low side compared to the rest of the industry. VVOS is outperformed by 77.45% of its industry peers.
Industry RankSector Rank
ROA -72.86%
ROE -140.01%
ROIC N/A
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
VVOS Yearly ROA, ROE, ROICVVOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

VVOS has a Gross Margin of 60.00%. This is amongst the best in the industry. VVOS outperforms 81.37% of its industry peers.
In the last couple of years the Gross Margin of VVOS has declined.
VVOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
VVOS Yearly Profit, Operating, Gross MarginsVVOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

VVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VVOS has been increased compared to 1 year ago.
The number of shares outstanding for VVOS has been increased compared to 5 years ago.
VVOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VVOS Yearly Shares OutstandingVVOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
VVOS Yearly Total Debt VS Total AssetsVVOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

VVOS has an Altman-Z score of -9.68. This is a bad value and indicates that VVOS is not financially healthy and even has some risk of bankruptcy.
VVOS has a Altman-Z score of -9.68. This is amonst the worse of the industry: VVOS underperforms 93.14% of its industry peers.
There is no outstanding debt for VVOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.68
ROIC/WACCN/A
WACC9.15%
VVOS Yearly LT Debt VS Equity VS FCFVVOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.50 indicates that VVOS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.50, VVOS is in line with its industry, outperforming 52.94% of the companies in the same industry.
A Quick Ratio of 1.50 indicates that VVOS should not have too much problems paying its short term obligations.
VVOS has a Quick ratio (1.50) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5
VVOS Yearly Current Assets VS Current LiabilitesVVOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

5

3. Growth

3.1 Past

VVOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.98%, which is quite impressive.
Looking at the last year, VVOS shows a quite strong growth in Revenue. The Revenue has grown by 8.91% in the last year.
The Revenue has been growing slightly by 5.70% on average over the past years.
EPS 1Y (TTM)83.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.39%
Revenue 1Y (TTM)8.91%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%-11.79%

3.2 Future

VVOS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.73% yearly.
VVOS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.29% yearly.
EPS Next Y55.48%
EPS Next 2Y30.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.8%
Revenue Next 2Y17.29%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VVOS Yearly Revenue VS EstimatesVVOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
VVOS Yearly EPS VS EstimatesVVOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VVOS. In the last year negative earnings were reported.
Also next year VVOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVOS Price Earnings VS Forward Price EarningsVVOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVOS Per share dataVVOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as VVOS's earnings are expected to grow with 30.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.73%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VVOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVOS THERAPEUTICS INC

NASDAQ:VVOS (5/23/2025, 9:02:54 PM)

After market: 2.27 -0.01 (-0.44%)

2.28

+0.19 (+9.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12
Inst Owners13.7%
Inst Owner Change12.11%
Ins Owners1.24%
Ins Owner Change0%
Market Cap13.43M
Analysts82.5
Price Target5.97 (161.84%)
Short Float %4.79%
Short Ratio3.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.11%
Min EPS beat(2)30.5%
Max EPS beat(2)35.71%
EPS beat(4)3
Avg EPS beat(4)18.55%
Min EPS beat(4)-36%
Max EPS beat(4)43.98%
EPS beat(8)5
Avg EPS beat(8)13.32%
EPS beat(12)7
Avg EPS beat(12)6.81%
EPS beat(16)7
Avg EPS beat(16)-0.15%
Revenue beat(2)0
Avg Revenue beat(2)-6.75%
Min Revenue beat(2)-6.81%
Max Revenue beat(2)-6.69%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-6.81%
Max Revenue beat(4)10.4%
Revenue beat(8)1
Avg Revenue beat(8)-7.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.14%
PT rev (3m)-7.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.44%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.89
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 2.83
EV/EBITDA N/A
EPS(TTM)-1.73
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-2.25
FCFYN/A
OCF(TTM)-2.15
OCFYN/A
SpS2.55
BVpS1.35
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.86%
ROE -140.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60%
FCFM N/A
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
F-Score4
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.76%
Cap/Sales 3.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z -9.68
F-Score4
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)121.46%
Cap/Depr(5y)141.96%
Cap/Sales(3y)5.11%
Cap/Sales(5y)6.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.39%
EPS Next Y55.48%
EPS Next 2Y30.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.91%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%-11.79%
Revenue Next Year13.8%
Revenue Next 2Y17.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.24%
OCF growth 3YN/A
OCF growth 5YN/A